Donor bone marrow type II (non-Vα14Jα18 CD1d-restricted) NKT cells suppress graft-versus-host disease by producing IFN-γ and IL-4

Journal of Immunology

Volumn 179, Issue 10, 2007, Pages 6579-6587

  Ji, Hyung Kim ^a   Eun, Young Choi ^a   Doo, Hyun Chung ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD1 ANTIGEN; CD1D ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; LYMPHOCYTE ANTIGEN RECEPTOR;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; ATTENUATION; BONE MARROW CELL; CONTROLLED STUDY; EXPERIMENTAL MOUSE; GRAFT VERSUS HOST REACTION; IMMUNE SYSTEM; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BONE MARROW TRANSPLANTATION; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; NATURAL KILLER CELL; PATHOLOGY; TH2 CELL;

ANIMALS; ANTIGENS, CD1; APOPTOSIS; BONE MARROW TRANSPLANTATION; GRAFT VS HOST DISEASE; INTERFERON TYPE II; INTERLEUKIN-4; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; TH2 CELLS;

EID: 38449096758     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.10.6579     Document Type: Article

References (41)

1. Taniguchi, M., M. Harada, S. Kojo, T. Nakayama, and H. Wakao. 2003. The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu. Rev. Immunol. 21: 483-513.
2. Kim, J. H., H. Y. Kim, S. Kim, J. H. Chung, W. S. Park, and D. H. Chung. 2005. Natural killer T (NKT) cells attenuate bleomycin-induced pulmonary fibrosis by producing interferon-γ. Am. J. Pathol. 167: 1231-1241.
3. Kim, H. J., S. J. Hwang, B. K. Kim, K. C. Jung, and D. H. Chung. 2006. NKT cells play critical roles in the induction of oral tolerance by inducing regulatory T cells producing IL-10 and transforming growth factor β, and by clonally deleting antigen-specific T cells. Immunology 118: 101-111.
4. Kim, H. J., H. Y. Kim, B. K. Kim, S. Kim, and D. H. Chung. 2006. Engagement of glucocorticoid-induced TNF receptor costimulates NKT cell activation in vitro and in vivo. J. Immunol. 176: 3507-3515.
5. Sharif, S., G. A. Arreaza, P. Zucker, Q. S. Mi, J. Sondhi, O. V. Naidenko, M. Kronenberg, Y. Koezuka, T. L. Delovitch, J. M. Gombert, et al. 2001. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes. Nat. Med. 7: 1057-1062.
6. + T cells reciprocally regulate acute graft versus host disease. J. Exp. Med. 189: 1073-1081.
7. Seino, K. I., K. Fukao, K. Muramoto, K. Yanagisawa, Y. Takada, S. Kakuta, Y. Iwakura, L. Van Kaer, K. Takeda, T. Nakayama, et al. 2001. Requirement for natural killer T (NKT) cells in the induction of allograft tolerance. Proc. Natl. Acad. Sci. USA 98: 2577-2581.
8. Cui, J., T. Shin, T. Kawano, H. Sato, E. Kondo, I. Toura, Y. Kaneko, H. Koseki, M. Kanno, and M. Taniguchi. 1997. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 278: 1623-1626.
9. Gonzalez-Aseguinolaza, G., L. Van Kaer, C. C. Bergmann, J. M. Wilson, J. Schmieg, M. Kronenberg, T. Nakayama, M. Taniguchi, Y. Koezuka, and M. Tsuji. 2002. Natural killer T cell ligand α-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med. 195: 617-624.
10. Kim, H. Y., H. J. Kim, H. S. Min, S. Kim, W. S. Park, S. H. Park, and D. H. Chung. 2005. NKT cells promote antibody-induced joint inflammation by suppressing transforming growth factor β1 production. J. Exp. Med. 201: 41-47.
11. Kronenberg, M., and L. Gapin. 2002. The unconventional lifestyle of NKT cells. Nat. Rev. Immunol. 2: 557-568.
12. - T cells in mice and humans. J. Exp. Med. 180: 1097-1106.
13. Bendelac, A. 1995. CD1: presenting unusual antigens to unusual T lymphocytes. Science 269: 185-186.
14. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, et al. 1997. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 278: 1626-1629.
15. Spada, F. M., Y. Koezuka, and S. A. Porcelli. 1998. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J. Exp. Med. 188: 1529-1534.
16. Duarte, N., M. Stenstrom, S. Campino, M. L. Bergman, M. Lundholm, D. Holmberg, and S. L. Cardell. 2004. Prevention of diabetes in nonobese diabetic mice mediated by CD1d-restricted nonclassical NKT cells. J. Immunol. 173: 3112-3118.
17. Terabe, M., J. Swann, E. Ambrosino, P. Sinha, S. Takaku, Y. Hayakawa, D. I. Godfrey, S. Ostrand-Rosenberg, M. J. Smyth, and J. A. Berzofsky. 2005. A nonclassical non-Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J. Exp. Med. 202: 1627-1633.
18. Baron, J. L., L. Gardiner, S. Nishimura, K. Shinkai, R. Locksley, and D. Ganem. 2002. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. Immunity 16: 583-594.
19. Fuss, I. J., F. Heller, M. Boirivant, F. Leon, M. Yoshida, S. Fichtner-Feigl, Z. Yang, M. Exley, A. Kitani, R. S. Blumberg, et al. 2004. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J. Clin. Invest. 113: 1490-1497.
20. Holler, E., H. J. Kolb, A. Moller, J. Kempeni, S. Liesenfeld, H. Pechumer, W. Lehmacher, G. Ruckdeschel, B. Gleixner, C. Riedner, et al. 1990. Increased serum levels of tumor necrosis factor α precede major complication of bone marrow transplantation. Blood 15: 1011-1016.
21. + T cells produce large amounts of IL-4 and IFN-γ upon activation by anti-CD3 or CD1. J. Immunol. 159: 2240-2249.
22. Akbari, O., P. Stock, E. Meyer, M. Kronenberg, S. Sidobre, T. Nakayama, M. Taniguchi, M. J. Grusby, R. H. DeKruyff, and D. T. Umetsu. 2003. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat. Med. 9: 582-588.
23. Liu, Y., and C. A. Janeway, Jr. 1990. Interferon γ plays a critical role in induced cell death of effector T cell: a possible third mechanism of self-tolerance. J. Exp. Med. 172: 1735-1739.
24. Yang, Y. G., B. R. Dey, J. J. Sergio, D. A. Pearson, and M. Sykes. 1998. Donor-derived interferon γ is required for inhibition of acute graft-versus-host disease by interleukin 12. J. Clin. Invest. 102: 2126-2135.
25. Refaeli, Y., L. Van Parijs, S. I. Alexander, and A. K. Abbas. 2002. Interferon γ is required for activation-induced death of T lymphocytes. J. Exp. Med. 196: 999-1005.
26. Reddy, P., T. Teshima, M. Kukuruga, R. Ordemann, C. Liu, K. Lowler, and J. L. Ferrara. 2001. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J. Exp. Med. 194: 1433-1440.
27. -/-) donors. Immunology 119: 338-347.
28. Crowe, N. Y., J. M. Coquet, S. P. Berzins, K. Kyparissoudis, R. Keating, D. G. Pellicci, Y. Hayakawa, D. I. Godfrey, and M. J. Smyth. 2005. Differential antitumor immunity mediated by NKT cell subsets in vivo. J. Exp. Med. 202: 1279-1288.
29. Seino, K., and M. Taniguchi. 2005. Functionally distinct NKT cell subsets and subtypes. J. Exp. Med. 202: 1623-1626.
30. Haraguchi, K., T. Takahashi, A. Matsumoto, T. Asai, Y. Kanda, M. Kurokawa, S. Ogawa, H. Oda, M. Taniguchi, H. Hirai, and S. Chiba. 2005. Host-residual invariant NK T cells attenuate graft-versus-host immunity. J. Immunol. 175: 1320-1328.
31. + T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: "natural suppressor" cells. J. Immunol. 167: 2087-2096.
32. Hashimoto, D., S. Asakura, S. Miyake, T. Yamamura, L. Van Kaer, C. Liu, M. Tanimoto, and T. Teshima. 2005. Stimulation of host NKT cells by synthetic glycolipid regulates acute graft-versus-host disease by inducing Th2 polarization of donor T cells. J. Immunol. 174: 551-556.
33. Zheng, L., G. Fisher, R. E. Miller, J. Peschon, D. H. Lynch, and M. J. Lenardo. 1995. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377: 348-351.
34. Ehl, S., U. Hoffmann-Rohrer, S. Nagata, H. Hengartner, and R. Zinkernagel. 1996. Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo. J. Immunol. 156: 2357-2360.
35. Brochu, S., B. Rioux-Masse, J. Roy, D. C. Roy, and C. Perreault. 1999. Massive activation-induced cell death of alloreactive T cells with apoptosis of bystander postthymic T cells prevents immune reconstitution in mice with graft-versus-host disease. Blood 94: 390-400.
36. + cells alleviates graft-versus-host disease in a murine model of semiallogeneic bone marrow transplantation: a potential role for NKT lymphocytes. Bone Marrow Transplant. 35: 191-197.
37. + natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γ production. Blood 97: 2923-2931.
38. Murphy, W. J., L. A. Welniak, D. D. Taub, R. H. Wiltrout, P. A. Taylor, D. A. Vallera, M. Kopf, H. Young, D. L. Longo, and B. R. Blazar. 1998. Differential effects of the absence of interferon-γ and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J. Clin. Invest. 102: 1742-1748.
39. Nikolic, B., S. Lee, R. T. Bronson, M. J. Grusby, and M. Sykes. 2000. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J. Clin. Invest. 105: 1289-1298.
40. Hill, G. R., K. R. Cooke, T. Teshima, J. M. Crawford, J. C. Keith, Jr., Y. S. Brinson, D. Bungard, and J. L. Ferrara. 1998. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Clin. Invest. 102: 115-123.
41. Reddy, P., T. Teshima, G. Hildebrandt, D. L. Williams, C. Liu, K. R. Cooke, and J. L. Ferrara. 2003. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood 101: 2877-2885.